衰老过程与一系列生理变化有关,这种变化可能影响药物处置和药动学。许多研究认为,年龄可以影响维拉帕米的处置。这些研究或只考虑单剂动力学或研究的年龄范围有限。因此,目前有关老年人维拉帕米稳态处置的报道十分有限。本文在74名(年龄19～79岁)血压正常健康志愿者(20名)和患轻、中度高血压病患者(54名)中,研究了年龄对维拉帕米稳态药动学的影响。所有受试者均符合下列要求:肝、肾功能正常,在研究前至少4周停服其它药物,不吸烟或至少戒烟6个月。随机将受试者分成三个年龄组:第一组19～44岁(26人,男16女10),第二组45～64岁 The aging process is associated with a series of physiological changes that may affect drug disposal and pharmacokinetics. Many studies suggest that age can affect the treatment of verapamil. These studies either consider only a single dose of kinetics or study the limited age range. Therefore, the current reports on the steady-state treatment of verapamil in the elderly are very limited. This study investigated the effects of age on steady-state pharmacokinetics of verapamil in 74 normotensive healthy volunteers (age 19-79), n = 20, and mild to moderate hypertensive patients (n = 54) influences. All subjects met the following criteria: Normal liver and kidney function, taking other medications at least 4 weeks prior to study, no smoking or at least 6 months of quitting smoking. Subjects were randomly divided into three age groups: the first group of 19 to 44 years (26, male 16 female 10), the second group of 45 to 64 years